FDA grants Teleflex breakthrough designation for resorbable magnesium coronary scaffold
The U.S. Food and Drug Administration awarded Breakthrough Device Designation to Teleflex’s Freesolve Resorbable Magnesium Scaffold, a temporary coronary vessel support that fully absorbs within a year. The designation is intended to speed development and review ahead of a future Premarket Approval application, and it aligns with the ongoing BIOMAG‑III pivotal trial. In the BIOMAG‑I first‑in‑human study, the scaffold exhibited a 3.5% target lesion failure rate after four years, with no additional events reported between years two and four. Teleflex highlighted that 99% of the magnesium alloy is absorbed at the 12‑month mark.
Why it matters
The breakthrough status may accelerate U.S. regulatory clearance, potentially expanding Teleflex’s revenue base beyond its current CE‑marked markets. The company suggests the device could reduce reliance on permanent implants and offer an alternative to drug‑coated balloons, which may affect market share in coronary interventions.
Key facts
- 1The FDA granted Breakthrough Device Designation to Teleflex’s Freesolve Resorbable Magnesium Scaffold. stocktitan.net
- 2The scaffold uses Teleflex’s proprietary BIOmag magnesium alloy and BIOlute bioabsorbable coating. stocktitan.net
- 399% of the magnesium is resorbed within 12 months. investing.com
- 4In the BIOMAG‑I First‑In‑Human study, the device showed a 3.5% target lesion failure rate after four years, with no new clinical events between years two and four. investing.com
- 5The device is currently CE‑marked and commercially available in Europe, Asia‑Pacific, South America and the Middle East. investing.com
- 6Teleflex plans to use the designation and the ongoing BIOMAG‑III pivotal trial to support a future U.S. Premarket Approval application. rttnews.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.